Using AI and drug modeling to understand why genes and other medicines change clopidogrel response
Official title: Merging artificial intelligence (AI) and pharmacometrics to elucidate gene-drug interactions linked to clopidogrel responsiveness in genetically heterogeneous patients
Funded at University of Puerto Rico Med Sciences · NIH-11376876 · Data updated 2026-11-12
This project uses AI, genetic data, and drug-response models to find why people with different genes or taking other medications respond differently to clopidogrel.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Puerto Rico Med Sciences NIH-funded |
| Lab location | 1 site (San Juan, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $149,000 |
| NIH project number | 5R16GM149372-04 |
| Project ID | NIH-11376876 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults taking clopidogrel—especially those also on cilostazol or other interacting drugs—who can provide medication history and genetic/sample data.
✕Less likely to help
People who are not taking clopidogrel or who are unwilling to provide genetic or medication information are unlikely to benefit directly from this project.
What this research studies
Researchers will combine genome-wide genetic data from diverse patients with machine-learning methods to create a weighted genetic risk score linked to clopidogrel response. They will build semi-mechanistic population pharmacokinetic–pharmacodynamic (PK–PD) models to simulate how co-medication with cilostazol and other drugs alters clopidogrel exposure and effect. The team will integrate the AI-derived risk scores and PK–PD results to identify the most important factors driving low or high drug response. Findings are intended to guide more personalized dosing and safer antiplatelet therapy.
Why it matters
Potential benefit: If successful, this work could help tailor clopidogrel dosing to a person’s genes and other medicines, reducing treatment failure and side effects.
How similar studies have gone: Previous research has shown that CYP2C19 genetics affect clopidogrel response, but combining GWAS-derived weighted risk scores, AI, and PK–PD modeling for drug–drug interactions is a novel approach.
Where this research is happening
-
University of Puerto Rico Med Sciences
San Juan, United States Active
Researchers
- Principal investigator: Duconge, Jorge — University of Puerto Rico Med Sciences
- Study coordinator: Duconge, Jorge
Related research
Other NIH-funded projects on the same topics.
-
Addressing fairness in AI models for asthma in young children
This grant aims to ensure AI tools used for diagnosing and managing asthma in children aged 0-11 work fairly for all socioeconomic and demographic groups.
-
AI-powered tools to improve periodontal diagnosis and treatment decisions
A dental AI tool helps doctors diagnose periodontitis more accurately and tailor care for adults, using 2D/3D images and health records.
-
Data and AI Core for Cardiovascular and Metabolic Health (Core D)
A central data and AI hub at the University of Louisville will help researchers collect, harmonize, and analyze data to understand how nutrition, metabolism, and heart health influence disease.
-
Making asthma care AI work fairly for all children
This project aims to improve AI tools used in pediatric asthma care so they give fairer and more reliable results for children from different incomes and backgrounds.
-
Using AI to improve safety in radiation therapy treatment planning
This study is testing a new AI tool to help doctors in radiation therapy work together better and make fewer mistakes before starting treatment, all to keep patients safer and improve their care.
-
Using artificial intelligence to improve treatment planning for patients in end-of-life care
This study is exploring how artificial intelligence can help doctors create personalized care plans for patients in end-of-life and palliative care, making sure that treatment choices reflect what patients and their families want while also looking at any concerns about fairness and patient control.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.